Table 2.

Treatment-emergent adverse events (TEAEs) overall summary

	Placebo (n=22)	RSLV-132 (n=42)
At least one TEAE	20 (90.9%)	36 (85.7%)
At least one severe TEAE	5 (22.7%)	3 (7.1%)
At least one study treatment-related TEAE	9 (40.9%)	15 (35.7%)
Study treatment discontinuation due to TEAE	4 (18.2%)	7 (16.7%)
Study termination due to TEAE	2 (9.1%)	6 (14.3%)
At least one treatment-emergent SAE	5 (22.7%)	3 (7.1%)
At least one study treatment-related treatment-emergent SAE	1 (4.5%)	1 (2.4%)

SAE, serious adverse event.